Skip to main content
. 2014 Jan 20;14:33. doi: 10.1186/1471-2407-14-33

Figure 2.

Figure 2

High prevalence of circulating YB-1/p18 in patients with various malignancies. (A) YB-1/p18 was previously measured in healthy volunteers (n = 60), patients with inflammatory or renal disease (n = 60), and patients with chronic liver disease (n = 91) with a low rate of YB-1/p18 positivity in patients without malignancies. In contrast, almost all patients with metastatic gastrointestinal tumors (n = 16) tested YB-1/p18 positive. (B) YB-1/p18 was detected in plasma samples of patients with malignant diseases with a rate of 62.5% (gastrointestinal [GI] tumors) to 100%. CUP, cancer of unknown primary site. (C) Cancer patients with or without detection of plasma YB-1/p18 did not differ with respect to their white-blood cell count (WBC), C-reactive protein (CRP) or lactate dehydrogenase (LDH); P > 0.05, not significant, U-Test. The box-and-whiskers plots display the median, quartiles, range and extreme values. The whiskers extend from the minimum to the maximum value excluding outside (>1.5 times upper/lower quartile, open circle) and “far out” (>3 time upper/lower quartile, asterisks) values.